These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 21931039)

  • 1. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
    Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
    Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
    Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
    Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
    Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
    In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
    Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
    Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
    Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
    Lans TE; Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM
    Ann Surg Oncol; 2005 May; 12(5):406-11. PubMed ID: 15915375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
    Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity.
    Bickels J; Manusama ER; Gutman M; Eggermont AM; Kollender Y; Abu-Abid S; Van Geel AN; Lev-Shlush D; Klausner JM; Meller I
    Eur J Surg Oncol; 1999 Oct; 25(5):509-14. PubMed ID: 10527599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
    Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
    Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.